NUVOLA, GIACOMO
 Distribuzione geografica
Continente #
NA - Nord America 410
EU - Europa 275
AS - Asia 249
AF - Africa 37
Totale 971
Nazione #
US - Stati Uniti d'America 408
SG - Singapore 97
IT - Italia 80
CN - Cina 54
SE - Svezia 51
VN - Vietnam 45
DE - Germania 29
IE - Irlanda 27
IN - India 23
CI - Costa d'Avorio 21
CH - Svizzera 20
JO - Giordania 20
BG - Bulgaria 18
GB - Regno Unito 18
FI - Finlandia 16
TG - Togo 12
RU - Federazione Russa 6
FR - Francia 5
HK - Hong Kong 4
ID - Indonesia 4
NG - Nigeria 4
NL - Olanda 3
CA - Canada 2
TR - Turchia 2
BE - Belgio 1
PL - Polonia 1
Totale 971
Città #
Singapore 88
Santa Clara 60
Chandler 43
Ashburn 32
Dong Ket 30
Dublin 27
Boardman 23
Fairfield 23
Abidjan 21
Amman 20
Bern 19
Sofia 18
Helsinki 16
Seattle 15
Woodbridge 15
Lomé 12
Princeton 12
Southend 12
Bologna 11
Houston 11
Wilmington 9
Cambridge 8
Beijing 7
Hyderabad 7
Moncalieri 7
Turin 7
Shanghai 6
Rome 5
Abeokuta 4
Guangzhou 4
Jakarta 4
Paris 4
Bari 3
Berlin 3
Des Moines 3
Genoa 3
London 3
San Diego 3
Verona 3
Ann Arbor 2
Boydton 2
Bremen 2
Brunswick 2
Bühl 2
Cagliari 2
Deiva Marina 2
Falkenstein 2
Gatineau 2
Hong Kong 2
Jinan 2
Los Angeles 2
Manchester 2
Nuremberg 2
Pune 2
Redmond 2
Shenzhen 2
Brussels 1
Böblingen 1
Changchun 1
Costa Mesa 1
Den Haag 1
Enschede 1
Florence 1
Fort Worth 1
Fremont 1
Genova 1
Hangzhou 1
Hounslow 1
Istanbul 1
Jiangmen 1
Jiaozuo 1
Jiaxing 1
Kuban 1
Lugano 1
Modena 1
Olalla 1
Phoenix 1
Quanzhou 1
Redwood City 1
Reggio Nell'emilia 1
San Francisco 1
Secaucus 1
Shaoyang 1
Shijiazhuang 1
Taiyuan 1
Trento 1
Warsaw 1
Washington 1
Westminster 1
Wuhan 1
Xi'an 1
Zhengzhou 1
Zhoukou 1
Totale 672
Nome #
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience 194
Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect 91
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution 73
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible? 70
Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases 66
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis 46
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 44
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 38
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 38
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 38
Development and Management of Massive Subcutaneous Metastases with Unusual Clinical Course from Uterine Leiomyosarcoma 38
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 37
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 35
Carboplatin, nab-paclitaxel plus atezolizumab in Impower 130 trial: New weapons beyond controversies 30
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 29
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 26
IMpower 132: Is the Second Exception to the Rule No Longer an Exception? 26
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 26
Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: Age, Eastern Cooperative Organization performance status 2, steroids and antibiotics 23
The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: Will immunotherapy solve the problem? 21
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 16
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) 15
Totale 1.020
Categoria #
all - tutte 4.312
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.312


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202010 0 0 0 0 0 0 0 0 5 2 3 0
2020/2021126 5 0 2 0 34 22 1 2 5 2 1 52
2021/2022117 5 0 3 3 6 4 3 12 12 10 42 17
2022/2023333 12 23 9 16 36 19 19 22 87 12 28 50
2023/2024145 24 25 16 11 11 37 0 6 2 7 4 2
2024/2025289 33 59 45 49 74 24 5 0 0 0 0 0
Totale 1.020